BSD Medical (BSDM) Sees Exit of Hyperthermia Product Line in Spring 2015; Offers Update on Strategic Plan

BSD Medical (NASDAQ: BSDM) provided an update on its strategic plan for the Company first outlined on January 12, 2015. As part of this plan, BSD intends to exit its hyperthermia product line this year and has submitted a non-binding term sheet for the potential sale of its assets. Terms are still being negotiated; however, the Company expects to close the transaction in spring 2015 if discussions progress as planned.

"We have received clear feedback from both Wall Street and strategic players that BSD will be a stronger and more attractive potential partner as a pure play microwave ablation company with a single, market leading product platform," said Clint Carnell, CEO of BSD Medical. "We are working to divest BSD's hyperthermia assets and obtain the highest valuation from it for shareholders as possible, all while focusing our realigned, leaner organization on the high growth, high margin microwave ablation platform exclusively."

Carnell continued, "In addition to our efforts to divest hyperthermia, we are moving swiftly, making important progress on our strategic plan, and are evaluating every available opportunity. For example, to capitalize on the robust local market for commercial real estate, we have decided to monetize the building we own in Salt Lake City by commencing a direct sale or sale-leaseback transaction. This will unlock capital we have tied up in real estate to help fund our growth initiatives."

Based on management's conversations to date with NASDAQ, BSD expects to receive an additional 180-day grace period on or around February 6, 2015 to regain compliance with the minimum bid price requirement and avoid delisting. As stated previously, the Company may be eligible to receive this additional grace period provided that it 1) meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market with the exception of the minimum bid price requirement, and 2) provides written notice of its intention to cure the minimum bid price deficiency during the second 180-day grace period by effecting a reverse stock split, if necessary.

"I am comfortable with the runway we have in front of us to deliver shareholder value. In the coming months, we intend to demonstrate progress to shareholders on our turnaround efforts, including reporting on microwave ablation case numbers and beginning to display revenue traction from our sales efforts," concluded Carnell.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• Oracle (ORCL) Introduces New AI Capabilities to Help Organizations Boost Sales